Groep Brussel Lambert NV (0IN2)
London Exchange · UK · prices in EUR · close of 21 Oct 2026
Key indicators
| Last close | EUR 74.15 |
|---|---|
| 52-week range | 68.00 – 83.35 |
| Return, 1 month / 3 months | −0.8% / −4.7% |
| Return, 1 year / 3 years | −0.0% / +22.1% |
| Trend | Below its 200-day average |
| RSI (14) | 64 |
| Volatility (1 year) | 15.8% |
| Worst drawdown (1 year) | -17.2% |
| Average daily value traded | 1.74M EUR |
| Dividend yield | 4.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Groupe Bruxelles Lambert is a Belgian holding company based in Brussels that invests in a range of businesses rather than making products itself. Its portfolio spans consumer goods, building materials, chemicals and other industries, with holdings in companies active in drinks, sportswear and industrial materials. The company acts as a long-term investor, supporting the management of the businesses it backs and managing a diversified collection of stakes on behalf of its shareholders.
On this site Groep Brussel Lambert NV appears as a stock on the London Exchange (UK), code 0IN2, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Groep Brussel Lambert NV (0IN2) trades on the London Exchange in UK. It last closed at EUR 74.15 on 21 October 2026.
Its price-based Market X-Ray is 58 out of 100 (a fair price profile), ranking 1,518 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 0.0% and over the last three months it fell 4.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 44 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -3.3% | ||
| From 52-week high | -10.5% | ||
| Momentum | 40 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -4.7% | ||
| 6-month return | -3.8% | ||
| 12-month return, skipping the last month | 0.8% | ||
| Stability (higher is calmer) | 87 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 15.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.2% | ||
| Liquidity | 59 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.74M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 64 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.8% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +4.6% |
|---|---|
| 1 month | −0.8% |
| 3 months | −4.7% |
| 6 months | −3.8% |
| 1 year | −0.0% |
| 3 years | +22.1% |
| 5 years | −11.6% |
Signals
| 50-day / 200-day average | 72.94 / 76.68 |
|---|---|
| Golden / death cross (60 days) | Death, 29 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.77 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 May 2026 | EUR 3.5875 |
| 9 May 2025 | EUR 3.5000 |
| 9 May 2024 | EUR 1.9250 |
| 11 May 2023 | EUR 1.9250 |
| 3 May 2022 | EUR 1.9250 |
| 4 May 2021 | EUR 1.7500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.